Eli Lilly and Company (NYSE:LLY) Shares Acquired by Oxford Financial Group Ltd.

Oxford Financial Group Ltd. lifted its position in Eli Lilly and Company (NYSE:LLY) by 2.3% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 187,873 shares of the company’s stock after purchasing an additional 4,212 shares during the quarter. Eli Lilly and Company comprises 7.2% of Oxford Financial Group Ltd.’s holdings, making the stock its 4th largest position. Oxford Financial Group Ltd.’s holdings in Eli Lilly and Company were worth $64,520,000 at the end of the most recent quarter.

Other institutional investors have also recently modified their holdings of the company. Banco Bilbao Vizcaya Argentaria S.A. raised its position in Eli Lilly and Company by 4.8% during the first quarter. Banco Bilbao Vizcaya Argentaria S.A. now owns 82,966 shares of the company’s stock valued at $28,449,000 after acquiring an additional 3,768 shares in the last quarter. L2 Asset Management LLC grew its holdings in Eli Lilly and Company by 4.5% in the first quarter. L2 Asset Management LLC now owns 2,014 shares of the company’s stock valued at $692,000 after purchasing an additional 86 shares during the period. Patten & Patten Inc. TN grew its holdings in Eli Lilly and Company by 44.2% in the first quarter. Patten & Patten Inc. TN now owns 17,177 shares of the company’s stock valued at $5,899,000 after purchasing an additional 5,266 shares during the period. Clal Insurance Enterprises Holdings Ltd acquired a new stake in Eli Lilly and Company in the first quarter valued at approximately $859,000. Finally, Jacobs & Co. CA grew its holdings in Eli Lilly and Company by 1.1% in the first quarter. Jacobs & Co. CA now owns 27,434 shares of the company’s stock valued at $9,421,000 after purchasing an additional 290 shares during the period. 81.38% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, major shareholder Lilly Endowment Inc sold 37,660 shares of the stock in a transaction dated Monday, August 28th. The stock was sold at an average price of $546,751.75, for a total transaction of $20,590,670,905.00. Following the transaction, the insider now owns 100,275,279 shares of the company’s stock, valued at approximately $54,825,684,274,988.30. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. In other Eli Lilly and Company news, EVP Johna Norton sold 1,647 shares of the stock in a transaction dated Wednesday, June 14th. The stock was sold at an average price of $444.29, for a total value of $731,745.63. Following the sale, the executive vice president now owns 31,761 shares of the company’s stock, valued at approximately $14,111,094.69. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Lilly Endowment Inc sold 37,660 shares of the stock in a transaction dated Monday, August 28th. The shares were sold at an average price of $546,751.75, for a total value of $20,590,670,905.00. Following the completion of the sale, the insider now directly owns 100,275,279 shares in the company, valued at approximately $54,825,684,274,988.30. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 828,161 shares of company stock valued at $20,988,181,235. Corporate insiders own 0.13% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have commented on LLY shares. 22nd Century Group reissued a “maintains” rating on shares of Eli Lilly and Company in a report on Tuesday, June 27th. Cantor Fitzgerald reissued an “overweight” rating and issued a $630.00 price objective on shares of Eli Lilly and Company in a report on Tuesday, August 22nd. Royal Bank of Canada lifted their price target on Eli Lilly and Company from $490.00 to $580.00 and gave the stock an “outperform” rating in a research note on Tuesday, August 8th. BMO Capital Markets lifted their price target on Eli Lilly and Company from $565.00 to $633.00 and gave the stock an “outperform” rating in a research note on Wednesday, August 9th. Finally, JPMorgan Chase & Co. lifted their price target on Eli Lilly and Company from $510.00 to $600.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 9th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and nineteen have issued a buy rating to the company. According to data from MarketBeat.com, Eli Lilly and Company presently has a consensus rating of “Moderate Buy” and an average target price of $520.48.

Eli Lilly and Company Trading Up 0.5 %

NYSE:LLY traded up $2.91 on Monday, reaching $557.11. The company’s stock had a trading volume of 2,030,800 shares, compared to its average volume of 3,011,057. The stock has a 50 day moving average price of $488.90 and a 200 day moving average price of $421.22. Eli Lilly and Company has a 12-month low of $296.32 and a 12-month high of $559.21. The company has a quick ratio of 0.87, a current ratio of 1.13 and a debt-to-equity ratio of 1.63. The firm has a market cap of $528.86 billion, a price-to-earnings ratio of 77.48, a price-to-earnings-growth ratio of 2.30 and a beta of 0.32.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Tuesday, August 8th. The company reported $2.11 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.98 by $0.13. Eli Lilly and Company had a return on equity of 65.00% and a net margin of 22.01%. The firm had revenue of $8.31 billion for the quarter, compared to analyst estimates of $7.58 billion. During the same quarter in the prior year, the company earned $1.25 EPS. Eli Lilly and Company’s revenue was up 28.1% on a year-over-year basis. On average, equities analysts anticipate that Eli Lilly and Company will post 9.83 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, September 8th. Investors of record on Tuesday, August 15th will be paid a dividend of $1.13 per share. This represents a $4.52 annualized dividend and a yield of 0.81%. The ex-dividend date of this dividend is Monday, August 14th. Eli Lilly and Company’s payout ratio is 62.87%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.